📰 Nuclear Export News

Page 18 - Nuclear Export News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

February 8, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

United States United Kingdom Kyongsang Bukto South Korea Region Flamande Sharon Shacham

Source: prnewswire.com

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

February 8, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

United States United Kingdom Kyongsang Bukto South Korea Region Flamande Sharon Shacham

Source: prnewswire.com

Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022

February 2, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

United Kingdom Selective Inhibitor Of Nuclear Export Prnewswire Karyopharm Therapeutics Inc Karyopharm Therapeutics Inc Karyopharm Therapeutics Selective Inhibitor

Source: prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

United Kingdom Selective Inhibitor Of Nuclear Export Karyopharm Therapeutics Inc Compensation Committee Of Karyopharm Board Directors Karyopharm Therapeutics Compensation Committee

Source: prnewswire.com

Karyopharm to Present at B. Riley Securities Oncology Investor Conference

January 21, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

United Kingdom Richard Paulson Selective Inhibitor Of Nuclear Export Prnewswire Karyopharm Therapeutics Inc Karyopharm Therapeutics Inc Chief Executive Officer

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

January 10, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

United States United Kingdom Richard Paulson Sohanya Cheng Selective Inhibitor Of Nuclear Export Karyopharm Therapeutics Inc

Source: prnewswire.com

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

January 10, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

United States United Kingdom Richard Paulson Sohanya Cheng Selective Inhibitor Of Nuclear Export Karyopharm Therapeutics Inc

Source: prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 3, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Prnewswire Karyopharm Therapeutics Inc Karyopharm Therapeutics Inc Karyopharm Selective Inhibitor Of Nuclear Export Compensation Committee Of Karyopharm Board Directors European Commission Compensation Committee

Source: prnewswire.com

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

December 30, 2021

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,...

Hong Kong South Korea Kevin Lynch Jay Mei Asia Pacific Peter Qian

Source: prnewswire.com